BioMarin Pharmaceutical (NASDAQ:BMRN) Updates FY 2026 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share guidance of 4.850-5.05 for the period, compared to the consensus earnings per share estimate of 4.980. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.7 billion.

BioMarin Pharmaceutical Stock Up 2.6%

Shares of NASDAQ:BMRN traded up $1.40 during midday trading on Monday, hitting $55.46. 2,807,634 shares of the company’s stock traded hands, compared to its average volume of 2,013,365. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.50 and a current ratio of 5.21. The company has a market cap of $10.72 billion, a PE ratio of 31.16, a P/E/G ratio of 0.54 and a beta of 0.23. The firm’s fifty day moving average price is $56.93 and its two-hundred day moving average price is $56.32. BioMarin Pharmaceutical has a twelve month low of $50.76 and a twelve month high of $66.28.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Monday, May 4th. The biotechnology company reported $0.76 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.18). The business had revenue of $766.21 million for the quarter, compared to analyst estimates of $752.15 million. BioMarin Pharmaceutical had a net margin of 10.83% and a return on equity of 7.91%. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.850-5.05 EPS. On average, equities research analysts anticipate that BioMarin Pharmaceutical will post 4.31 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BMRN has been the topic of several recent research reports. Loop Capital set a $105.00 target price on shares of BioMarin Pharmaceutical in a report on Monday, March 2nd. Guggenheim reduced their target price on shares of BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating on the stock in a report on Wednesday, February 25th. Truist Financial upgraded shares of BioMarin Pharmaceutical to a “strong-buy” rating in a report on Wednesday, March 25th. Bank of America reduced their target price on shares of BioMarin Pharmaceutical from $97.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, March 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $103.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.48.

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, EVP Charles Greg Guyer sold 16,486 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the sale, the executive vice president owned 79,953 shares of the company’s stock, valued at $4,833,958.38. The trade was a 17.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gregory R. Friberg sold 6,326 shares of BioMarin Pharmaceutical stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the sale, the executive vice president directly owned 37,578 shares in the company, valued at $2,268,959.64. This trade represents a 14.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Viking Global Investors LP increased its position in shares of BioMarin Pharmaceutical by 13.8% in the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock worth $675,505,000 after purchasing an additional 1,488,552 shares during the last quarter. AQR Capital Management LLC increased its position in shares of BioMarin Pharmaceutical by 12.7% in the 4th quarter. AQR Capital Management LLC now owns 6,686,916 shares of the biotechnology company’s stock worth $395,197,000 after purchasing an additional 754,807 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of BioMarin Pharmaceutical by 48.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,321,754 shares of the biotechnology company’s stock worth $197,405,000 after purchasing an additional 1,076,568 shares during the last quarter. Vestal Point Capital LP increased its position in shares of BioMarin Pharmaceutical by 261.4% in the 4th quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock worth $178,290,000 after purchasing an additional 2,170,000 shares during the last quarter. Finally, Northern Trust Corp increased its position in shares of BioMarin Pharmaceutical by 0.4% in the 3rd quarter. Northern Trust Corp now owns 1,662,268 shares of the biotechnology company’s stock worth $90,028,000 after purchasing an additional 7,157 shares during the last quarter. Hedge funds and other institutional investors own 98.71% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.